Advanced-stage cHL: Rethinking Our Options in Frontline Therapy
 | Advanced-stage cHL: Rethinking Our Options in Frontline Therapy CME, CPE Jonathon B. Cohen, MD, MS | |
| Release Date: October 17, 2018 Expiration Date: October 17, 2019 | ||
| New strategies are emerging to improve the frontline treatment of patients with newly diagnosed advanced-stage classical Hodgkin lymphoma (cHL). In this interview, Dr. Jonathon Cohen discusses results from recent clinical trials that are making an impact on the frontline management of advanced-stage cHL. He also outlines how these advances will influence clinical practice and positively impact current standards of care for the disease. Provided by MediCom Worldwide, Inc. This activity is supported by educational grants from Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics, Inc. | ||
| View Only, CE ExpiredView Only, No Credit | ||